Omecod (Omeprazole)

Omeprazole, the active ingredient in Omecod, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to manage gastro‑reflux and related conditions in adults. GNH USA supplies Omecod as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omecod as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omecod is a proton pump inhibitor that acts on the acid‑secretion pathway of the stomach. It is indicated for several gastrointestinal conditions: - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of the esophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the syndrome. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer formation in patients regularly using non‑steroidal anti‑inflammatory drugs.

Adverse reactions to Omecod may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: typically self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased gas production. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention. - Clostridioides difficile infection: may present with persistent diarrhea. - Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia. - Bone fractures: associated with long‑term use. - Acute interstitial nephritis: renal inflammation requiring evaluation. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare severe skin reactions.

When using Omecod, consider the following safety measures: - Assess renal function: adjust use in patients with severe kidney impairment. - Review hepatic status: use with caution in moderate to severe liver disease. - Monitor long‑term therapy: evaluate need for continued treatment after 12 months. - Avoid abrupt discontinuation: taper if therapy has been long‑term to reduce rebound acid hypersecretion. - Drug‑interaction review: check concomitant medications for potential interactions. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omecod can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Digoxin: possible rise in serum levels. - Methotrexate: reduced renal clearance may elevate toxicity risk. - Phenytoin: may lower phenytoin concentrations. - Iron supplements: decreased absorption, advise spacing doses.